See more : Toucan Interactive Corp. (TCNT) Income Statement Analysis – Financial Results
Complete financial analysis of Scinai Immunotherapeutics Ltd. (SCNI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scinai Immunotherapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Intouch Holdings Public Company Limited (INTUCH.BK) Income Statement Analysis – Financial Results
- Paras Defence and Space Technologies Limited (PARAS.BO) Income Statement Analysis – Financial Results
- Yunji Inc. (YJ) Income Statement Analysis – Financial Results
- Taiwan Thick-Film Ind. Corp (6246.TWO) Income Statement Analysis – Financial Results
- The Akita Bank, Ltd. (8343.T) Income Statement Analysis – Financial Results
Scinai Immunotherapeutics Ltd. (SCNI)
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.98K | 76.22K | 66.96K | 73.42K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -167.98K | -76.22K | -66.96K | -73.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 5.77M | 3.25M | 16.01M | 19.88M | 19.27M | 5.58M | 2.44M | 2.76M | 1.65M | 1.94M | 1.61M | 1.53M | 1.80M | 805.34K | 882.39K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.51M | 5.30M | 7.63M | 5.19M | 2.81M | 1.38M | 1.40M | 1.07M | 871.81K | 680.13K | 631.56K | 574.69K | 602.75K | 668.83K | 299.68K | 343.07K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -23.49M | 1.00 | -38.24K | -185.65K | -416.06K | -726.29K | -243.56K | -366.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.19M | 2.13M | 2.47M | 1.11M | 1.23M |
| Cost & Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.38M | 2.30M | 2.54M | 1.17M | 1.30M |
| Interest Income | 122.68K | 8.10M | 928.76 | -9.71K | 8.30K | 1.35M | 5.04K | 14.38K | 2.83K | 21.19K | 37.80K | 65.04K | 129.34K | 85.62K | 8.66K | 89.89K |
| Interest Expense | -317.00 | 5.05M | -3.15M | 338.76K | 4.28M | 3.78M | -129.95 | 100.00 | 7.80 | 1.69K | -1.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 514.00K | 562.00K | 471.00K | 468.56K | 461.69K | 69.53K | 123.55K | 162.32K | 161.62K | 173.75K | 204.46K | 190.18K | 167.98K | 76.22K | 66.96K | 73.42K |
| EBITDA | -9.19M | -10.50M | -10.39M | 2.75M | -22.21M | -20.54M | -6.67M | -2.93M | -2.74M | -1.92M | -2.00M | -2.24M | -1.99M | -2.41M | -1.10M | -1.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.72M | -11.06M | -10.87M | 2.28M | -22.69M | -20.61M | -6.80M | -3.09M | -2.90M | -2.09M | -2.20M | -2.38M | -2.30M | -2.54M | -1.17M | -1.30M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.22M | 5.27M | 2.67M | -3.67M | -8.93M | -2.85M | -3.13M | 704.94K | 283.33K | 97.02K | -113.91K | -51.25K | 142.22K | 53.68K | 6.87K | 88.21K |
| Income Before Tax | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.35 | -230.45 | -223.97 | -279.13 | -173.14 | -189.82 |
| EPS Diluted | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.33 | -230.45 | -223.97 | -279.13 | 0.00 | -189.82 |
| Weighted Avg Shares Out | 390.66K | 188.52K | 141.14K | 110.81K | 81.66K | 65.35K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 6.73K | 6.38K |
| Weighted Avg Shares Out (Dil) | 390.66K | 188.52K | 141.14K | 110.82K | 81.66K | 65.36K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 0.00 | 6.38K |
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
JERUSALEM , Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024...
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
JERUSALEM , Jan. 4, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological therapeutic products and provision of boutique CDMO services, today announced the closing of its previously announced...
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
JERUSALEM , Jan. 4, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, today published a letter from its CEO, Amir Reichman, addressing the Company's 2023 accomplishments, including successful preclinical...
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
JERUSALEM , Dec. 29, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological therapeutic products and provision of boutique CDMO services, today announced the entry into a definitive agreement...
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
JERUSALEM , Dec. 27, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological products and provision of boutique CDMO services, announced today that the Company will host an analyst...
Scinai Announces Promising Results in a Psoriatic Human Skin Model
JERUSALEM , Dec. 12, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology biological products, is pleased to announce today successful preclinical trial results of its innovative anti–IL–17 VHH antibody ('NanoAb')...
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, addressing significant medical needs JERUSALEM , Dec. 11, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation...
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
Significant positive impact to Scinai's financial health is expected Amendment made in light of Scinai's recent strategic shift to development of nanosized antibody therapeutics aimed at inflammation and immunology diseases JERUSALEM , Nov. 29, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI)...
Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule
JERUSALEM , Nov. 20, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced today the receipt of formal notification from the Nasdaq Stock Market ("Nasdaq") that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders' equity.
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant covering 66% of the costs of an ILS 3,536,939 (approximately US$900,000) project...
Source: https://incomestatements.info
Category: Stock Reports